Bambusa Therapeutics files for IPO, discloses bispecific antibody data

Bambusa Therapeutics, Inc. filed a Form S-1 registration statement with the SEC on October 9, 2026 for its initial public offering. The filing covers common stock and the company has applied to list on the Nasdaq Global Select Market under the symbol "BBTX."¹

Bambusa describes itself as a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed for immunology and inflammation.¹ Its lead candidate, BBT001, targets IL-4Rα and IL-31 pathways and is being evaluated for moderate-to-severe atopic dermatitis in a global Phase 1 trial across the United States, Australia, Europe and New Zealand, as well as in a Phase 1a/1b trial in China.¹

In July 2026, the company reported positive topline proof-of-concept results from the Global BBT001 Study, based on 17 enrolled bio-naïve AD patients evaluable as of a June 8, 2026 data cutoff.¹ At Week 6, the placebo-adjusted proportion of patients achieving EASI-50 and EASI-75 was 82% and 64%, respectively.¹

The company's second lead candidate, BBT002, targets IL-4Rα and IL-5 and is being evaluated in a global Phase 1 study for chronic obstructive pulmonary disease and in a Phase 1/2a China study.¹

As of June 30, 2026, Bambusa had raised $136.1 million in gross proceeds through private financings with investors including ATHOS, BVF Partners, Dawn Biopharma, INCE Capital, RA Capital and Salvia.¹ The company's management has concluded there is substantial doubt about its ability to continue as a going concern, which it says could mean stockholders lose some or all of their investment if that doubt is not resolved.¹ Pricing terms and share counts were not yet specified in the filing.